PALI
Palisade Bio, Inc.
NASDAQ · USHealthcareBiotechnology
$1.91-3.05%
Price as of Jul 20, 2026
PALI financials
Palisade Bio, Inc. financial statements
Annual and quarterly income statement, balance sheet and cash-flow history. On small screens, start with four periods and expand the table when needed.
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Income statement | ||||
| Revenue | $0.00 | $0.00 | $250.0K | $0.00 |
| Cost of revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross profit | $0.00 | $0.00 | $250.0K | $0.00 |
| Operating expenses | $18.1M | $14.9M | $13.3M | $15.7M |
| Operating income | -$18.1M | -$14.9M | -$13.1M | -$15.7M |
| Net income | -$16.8M | -$14.4M | -$12.3M | -$14.3M |
| EBITDA | -$16.8M | -$14.4M | -$12.3M | -$14.2M |
| Basic EPS | $-0.30 | $-10.19 | $-27.01 | $-16.53 |
| Diluted EPS | $-0.30 | $-10.19 | $-27.01 | $-16.53 |
| Balance sheet | ||||
| Cash & equivalents | $133.4M | $9.8M | $12.4M | $12.4M |
| Total assets | $134.3M | $10.9M | $14.1M | $15.8M |
| Total liabilities | $5.0M | $3.4M | $2.7M | $3.3M |
| Stockholders’ equity | $129.4M | $7.5M | $11.3M | $12.5M |
| Total debt | $71.0K | $169.0K | $369.0K | $404.0K |
| Net debt | -$133.3M | -$9.7M | -$12.1M | -$12.0M |
| Cash flow | ||||
| Operating cash flow | -$10.8M | -$12.2M | -$11.1M | -$13.4M |
| Capital expenditure | $0.00 | $0.00 | -$4.0K | -$10.0K |
| Free cash flow | -$10.8M | -$12.2M | -$11.1M | -$13.4M |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 |
| Share repurchases | $0.00 | $0.00 | $0.00 | $0.00 |